Due to the rapidly developing nature of the current COVID-19 outbreak and its almost immediate humanitarian and economic toll, coronavirus drug discovery efforts have largely focused on generating potential COVID-19 drug candidates as quickly as possible. Globally, scientists are working day and night to find the best possible solution to treat the deadly virus. During the first few months of 2020, the SARS-CoV-2 outbreak quickly developed into a pandemic, with a mortality rate that was increasing at an exponential rate day by day. As a result, scientists have turned to a drug repurposing approach to rediscover the potential use and benefits of existing approved drugs. Currently, there is no single drug approved by the U.S. Food and Drug Administration (FDA), for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously known as 2019-nCoV) that causes COVID-19. Based on only in-vitro studies, several active drugs are already in the clinical pipeline, made possible by following the compassionate use of medical protocols. This method of repurposing and the use of existing molecules like Remdesivir (GS-5734), Chloroquine, Hydroxychloroquine, etc. has proven to be a landmark in the field of drug rediscovery. In this review article, we will discuss the repurposing of medicines for treating the deadly novel coronavirus (SARS-CoV-2).

由于当前COVID-19爆发的迅速发展性质及其几乎立即造成的人道主义和经济损失，冠状病毒药物的发现工作主要集中在尽快生成潜在的COVID-19候选药物上。在全球范围内，科学家们日夜不停地寻找治疗致命病毒的最佳解决方案。在2020年的头几个月中，SARS-CoV-2爆发迅速发展成为大流行病，死亡率呈指数级增长。结果，科学家们转向了药物重新利用的方法，以重新发现现有批准药物的潜在用途和益处。目前，尚无美国食品药品监督管理局（FDA）批准的用于治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2，以前称为2019-nCoV）导致COVID-19。仅根据体外研究，通过对医疗方案的体贴使用，几种活性药物已经在临床上。这种重新利用的方法和使用现有分子，如伦德斯韦（GS-5734），氯喹，羟基氯喹等，已被证明是药物重新发现领域的一个里程碑。在这篇评论文章中，我们将讨论用于治疗致命性新型冠状病毒（SARS-CoV-2）的药物的重新用途。等已被证明是药物重新发现领域的里程碑。在这篇评论文章中，我们将讨论用于治疗致命性新型冠状病毒（SARS-CoV-2）的药物的重新用途。等已被证明是药物重新发现领域的里程碑。在这篇综述文章中，我们将讨论用于治疗致命性新型冠状病毒（SARS-CoV-2）的药物的重新用途。